Loading...
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
BACKGROUND: Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we anal...
Na minha lista:
| Udgivet i: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057434/ https://ncbi.nlm.nih.gov/pubmed/32111729 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000438 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|